The Tau Tubulin Kinases TTBK1/2 Promote Accumulation of Pathological TDP-43

PLoS Genetics

Volumn 10, Issue 12, 2014, Pages

  Liachko, Nicole F ^a,b   McMillan, Pamela J ^a,b   Strovas, Timothy J ^a   Loomis, Elaine ^a   Greenup, Lynne ^a   Murrell, Jill R ^c   Ghetti, Bernardino ^c   Raskind, Murray A ^a,b   Montine, Thomas J ^a,d   Bird, Thomas D ^a,b,d   Leverenz, James B ^a,b,d   Kraemer, Brian C ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAR DNA BINDING PROTEIN; TUBULIN; TUBULIN KINASE 1; TUBULIN KINASE 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TAU-TUBULIN KINASE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN REGION; CELL NUCLEUS; CYTOPLASM; FRONTAL CORTEX; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; MOTOR PERFORMANCE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; ANIMAL; CAENORHABDITIS ELEGANS; CELL CULTURE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN DEGRADATION; RNA INTERFERENCE; TRANSGENIC ANIMAL;

CAENORHABDITIS ELEGANS; MAMMALIA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CELLS, CULTURED; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL LOBAR DEGENERATION; GENE EXPRESSION PROFILING; HEK293 CELLS; HUMANS; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; RNA INTERFERENCE;

EID: 84919663858     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004803     Document Type: Article

References (65)

1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602–611.
2. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133.
3. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, et al. (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 4: e1000193.
4. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668–1672.
5. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572–574.
6. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, et al. (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7: 409–416.
7. Kuhnlein P, Sperfeld AD, Vanmassenhove B, Van Deerlin V, Lee VM, et al. (2008) Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol 65: 1185–1189.
8. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, et al. (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69: 918–929.
9. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL, (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67: 1159–1165.
10. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, et al. (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114: 221–229.
11. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, et al. (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 1184: 284–294.
12. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, et al. (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 61: 435–445.
13. Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, et al. (2013) TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 70: 1418–1424.
14. Liachko NF, Guthrie CR, Kraemer BC, (2010) Phosphorylation Promotes Neurotoxicity in a Caenorhabditis elegans Model of TDP-43 Proteinopathy. J Neurosci 30: 16208–16219.
15. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, et al. (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 19: 671–683.
16. Lu Y, Ferris J, Gao FB, (2009) Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol Brain 2: 30.
17. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH, (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 106: 18809–18814.
18. Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL, (2010) Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis 40: 404–414.
19. Zhou H, Huang C, Chen H, Wang D, Landel CP, et al. (2010) transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet 6: e1000887.
20. Lee EB, Lee VM, Trojanowski JQ, (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13: 38–50.
21. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64: 60–70.
22. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, et al. (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117: 137–149.
23. Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, et al. (2013) CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol 74: 39–52.
24. Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, et al. (2014) Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. J Med Chem 57: 2755–2772.
25. Manning G, (2005) Genomic overview of protein kinases. WormBook 1–19.
26. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403–410.
27. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, et al. (2008) Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 36: W465–469.
28. Ikezu S, Ikezu T, (2014) Tau-tubulin kinase. Front Mol Neurosci 7: 33.
29. Ren M, Feng H, Fu Y, Land M, Rubin CS, (2009) Protein kinase D is an essential regulator of C. elegans innate immunity. Immunity 30: 521–532.
30. Fu Y, Rubin CS, (2011) Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology. EMBO Rep 12: 785–796.
31. Sato S, Cerny RL, Buescher JL, Ikezu T, (2006) Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem 98: 1573–1584.
32. Flotow H, Graves PR, Wang AQ, Fiol CJ, Roeske RW, et al. (1990) Phosphate groups as substrate determinants for casein kinase I action. J Biol Chem 265: 14264–14269.
33. Streets AJ, Needham AJ, Gill SK, Ong AC, (2010) Protein kinase D-mediated phosphorylation of polycystin-2 (TRPP2) is essential for its effects on cell growth and calcium channel activity. Mol Biol Cell 21: 3853–3865.
34. Sturany S, Van Lint J, Muller F, Wilda M, Hameister H, et al. (2001) Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem 276: 3310–3318.
35. Takahashi M, Tomizawa K, Sato K, Ohtake A, Omori A, (1995) A novel tau-tubulin kinase from bovine brain. FEBS Lett 372: 59–64.
36. Iguchi Y, Katsuno M, Takagi S, Ishigaki S, Niwa J, et al. (2012) Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis 45: 862–870.
37. Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L, (2003) Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci 207: 51–58.
38. Takahashi M, Tomizawa K, Sato K, Ohtake A, Omori A, (1995) A novel tau-tubulin kinase from bovine brain. FEBS Lett 372: 59–64.
39. Tomizawa K, Omori A, Ohtake A, Sato K, Takahashi M, (2001) Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. Febs Letters 492: 221–227.
40. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, et al. (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122: 111–113.
41. Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, et al. (2008) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 582: 2899–2904.
42. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2005) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 33: D39–45.
43. Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, et al. (2009) Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun 382: 405–409.
44. Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoum MF, et al. (2014) TDP-43 Phosphorylation by casein kinase Iε promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet 23: 1025–1035.
45. Carlomagno Y, Zhang Y, Davis M, Lin WL, Cook C, et al. (2014) Casein Kinase II Induced Polymerization of Soluble TDP-43 into Filaments Is Inhibited by Heat Shock Proteins. PLoS One 9: e90452.
46. Hanger DP, Betts JC, Loviny TLF, Blackstock WP, Anderton BH, (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. Journal of Neurochemistry 71: 2465–2476.
47. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, et al. (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67: 555–564.
48. Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, et al. (2010) Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 120: 55–66.
49. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, et al. (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122: 137–153.
50. Vázquez-Higuera JL, Martínez-García A, Sánchez-Juan P, Rodríguez-Rodríguez E, Mateo I, et al. (2011) Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort. Neurobiol Aging 32: 550.e555–559.
51. Yu NN, Yu JT, Xiao JT, Zhang HW, Lu RC, et al. (2011) Tau-tubulin kinase-1 gene variants are associated with Alzheimer's disease in Han Chinese. Neurosci Lett 491: 83–86.
52. Lund H, Cowburn RF, Gustafsson E, Stromberg K, Svensson A, et al. (2013) Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain. Brain Pathol 23: 378–389.
53. Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, et al. (2008) Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 28: 14511–14521.
54. Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, et al. (2010) Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB J 24: 2904–2915.
55. Houlden H, Johnson J, Gardner-Thorpe C, Lashley T, Hernandez D, et al. (2007) Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 39: 1434–1436.
56. Bouskila M, Esoof N, Gay L, Fang EH, Deak M, et al. (2011) TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. Biochem J 437: 157–167.
57. Brenner S, (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94.
58. Plowman GD, Sudarsanam S, Bingham J, Whyte D, Hunter T, (1999) The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc Natl Acad Sci U S A 96: 13603–13610.
59. Wang D, Kennedy S, Conte D, Kim JK, Gabel HW, et al. (2005) Somatic misexpression of germline P granules and enhanced RNA interference in retinoblastoma pathway mutants. Nature 436: 593–597.
60. Kraemer BC, Schellenberg GD, (2007) SUT-1 enables tau-induced neurotoxicity in C. elegans. Hum Mol Genet 16: 1959–1971.
61. Guthrie CR, Schellenberg GD, Kraemer BC, (2009) SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum Mol Genet 18: 1825–1838.
62. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, et al. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 280: 37572–37584.
63. Goetz SC, Liem KF, Anderson KV, (2012) The spinocerebellar ataxia-associated gene Tau tubulin kinase 2 controls the initiation of ciliogenesis. Cell 151: 847–858.
64. Oliveira VC, Carrara RC, Simoes DL, Saggioro FP, Carlotti CG, et al. (2010) Sudan Black B treatment reduces autofluorescence and improves resolution of in situ hybridization specific fluorescent signals of brain sections. Histol Histopathol 25: 1017–1024.
65. Kitano-Takahashi M, Morita H, Kondo S, Tomizawa K, Kato R, et al. (2007) Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 602–604.